Experimental study of an antitumor preparation proloteston

The results of an experimental evaluation of a prolonged action antitumor drug--prolotestone are presented. The drug is a mixture of steroids of the androstane series, 2 alpha-methylhydrotestosterone and its three esters. The preparation has been approved for medication. Prolotestone treatment in th...

Full description

Saved in:

Bibliographic Details
Published in:	Voprosy onkologij Vol. 29; no. 3; p. 82
Main Authors:	Beskrovnyĭ, A M, Sof'ina, Z P, Sukhacheva, O A, Ushenko, S N, Iurchenko, M Z
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 1983
Subjects:	Androstanols - administration & dosage Androstanols - analogs & derivatives Androstanols - therapeutic use Animals Antineoplastic Agents - administration & dosage Drug Therapy, Combination Female Mammary Neoplasms, Experimental - drug therapy Melphalan - administration & dosage Rats
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The results of an experimental evaluation of a prolonged action antitumor drug--prolotestone are presented. The drug is a mixture of steroids of the androstane series, 2 alpha-methylhydrotestosterone and its three esters. The preparation has been approved for medication. Prolotestone treatment in the dose of 14 mg once in two weeks produced a high antiblastogenic effect in rats with hormone-dependent cancer of the mammary gland induced by dimethylbenz(a)anthracene. It was shown in tests involving the use of a number of transplantable tumors that prolotestone potentiates the antitumor effect of sarcolysin and mitigates its untoward side-effects. The preparation is practically non-toxic, possesses a high anabolic index, has a beneficial effect on hepatic function and lowers the glucocorticoid function of the adrenals. It is thought that application of the drug should not be limited to the treatment of breast cancer.
ISSN:	0507-3758